Literature DB >> 27884136

Erratum to: Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival.

Sigurd M Hald¹, Yury Kiselev^2,3, Samer Al-Saad^2,4, Elin Richardsen^2,4, Charles Johannessen², Marte Eilertsen⁵, Thomas K Kilvaer⁶, Khalid Al-Shibli^2,7, Sigve Andersen^5,6, Lill-Tove Busund^2,4, Roy M Bremnes^5,6, Tom Donnem^5,6.

Abstract

Entities: CellLine Disease Gene Species

Year: 2016 PMID： 27884136 PMCID： PMC5122019 DOI： 10.1186/s12885-016-2954-1

Source DB: PubMed Journal: BMC Cancer ISSN： 1471-2407 Impact factor: 4.430

× No keyword cloud information.

Erratum

After publication of the original article [1], the author noticed that there are some error with Table 2 and Table 3. Please see the correct Tables below. We apologize for any inconvenience caused.

Table 2

CXCL16 and CXCR6 expression as predictors of disease-specific survival in 335 NSCLC patients

Characteristics	Patients, N (%)	Median survival (months)	5-year survival (%)	P
CXCL16
Cancer cells				.080
High	48 (14)	NR	67
Low	227 (68)	98	56
Missing	60 (18)
Stromal cells				.016
High	258 (77)	189	62
Low	43 (13)	57	48
Missing	34 (10)
CXCR6
Cancer cells				.093
High	41 (12)	190	73
Low	245 (73)	122	55
Missing	49 (15)
CXCL16
Cancer cells + stromal cells combined				.016
High/High	43 (13)	NR	71
High/Low	182 (54)	190	58
Low/Low	41 (12)	47	48
Missing	69 (21)

NR, not reached; NCSLC, non-small cell lung cancer. Bold values indicate p < 0.05

Table 3

Results of multivariate Cox regression analyses for clinicopathological factors and CXCL16 in stromal cells (model 1) and co-expression of CXCL16 in cancer and stromal cells (model 2*)

Factor	HR	CI 95%	P
T-status			<0.001 ^†
T1	1.00
T2	1.60	(0.97-2.64)	0.065
T3	3.80	(2.13-6.77)	<0.001
N-status			<0.001 ^†
N0	1.00
N1	2.01	(1.30-3.11)	0.002
N2	3.08	(1.74-5.44)	<0.001
Differentiation			0.009 ^†
Well	1.00
Moderate	1.17	(0.63-2.20)	0.618
Poor	2.08	(1.12-3.85)	0.020
Performance status			0.040 ^†
ECOG 0	1.00
ECOG 1	1.52	(1.02-2.26)	0.040
ECOG 2	2.15	(0.94-4.91)	0.069
Vascular infiltration
No	1.00
Yes	1.70	(1.01-2.87)	0.046
Histology			<0.001 ^†
Squamous carcinoma	1.00
Adenocarcinoma	2.23	(1.48-3.35)	<0.001
Large cell carcinoma	0.80	(0.39-1.66)	0.555
CXC16 stromal cells
Low	1
High	0.55	(0.35-0.87)	0.011
CXCL16 cancer and stromal cells*			0.031 ^†
Low/Low	1.00
Low/High + High/Low	0.57	(0.35-0.93)	0.023
High/High	0.42	(0.20-0.88)	0.022

†Overall significance as prognostic marker. HR, Hazard ratio. Bold values indicate p < 0.05

CXCL16 and CXCR6 expression as predictors of disease-specific survival in 335 NSCLC patients NR, not reached; NCSLC, non-small cell lung cancer. Bold values indicate p < 0.05 Results of multivariate Cox regression analyses for clinicopathological factors and CXCL16 in stromal cells (model 1) and co-expression of CXCL16 in cancer and stromal cells (model 2*) †Overall significance as prognostic marker. HR, Hazard ratio. Bold values indicate p < 0.05

1 in total

1. Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival.

Authors: Sigurd M Hald; Yury Kiselev; Samer Al-Saad; Elin Richardsen; Charles Johannessen; Marte Eilertsen; Thomas K Kilvaer; Khalid Al-Shibli; Sigve Andersen; Lill-Tove Busund; Roy M Bremnes; Tom Donnem
Journal: BMC Cancer Date: 2015-05-29 Impact factor: 4.430

1 in total

1. Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways in gastric cancer.

Authors: Xueying Lu; Yanhong Li; Xiaobo Li; Haji Akber Aisa
Journal: Oncol Lett Date: 2017-06-14 Impact factor: 2.967

1 in total